Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
DEA places CUMYL-PEGACLONE (a synthetic cannabinoid) into Schedule I, making it illegal to manufacture, distribute, or possess. This does not affect hemp or cannabis operators unless they handle this specific substance.
Aforeworn detected this change in the Cannabis & Hemp Operators space on July 5, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Cannabis and hemp operators, especially those producing or selling synthetic cannabinoids or unregulated THC analogs. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication (May 13, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cannabis & Hemp Operators continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
CUMYL-PEGACLONE is now a Schedule I controlled substance under federal law.
Who it affects
Cannabis and hemp operators, especially those producing or selling synthetic cannabinoids or unregulated THC analogs.
What you must do
Ensure no products contain CUMYL-PEGACLONE; review ingredient lists and supply chains.
Deadline
Immediately upon publication (May 13, 2026).
Never miss a change like this again
Aforeworn watches Cannabis & Hemp Operators around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cannabis & Hemp Operators
- Oregon Liquor and Cannabis Commission : Marijuana and Hemp (Cannabis) : Marijuana and Hemp (Cannabis) : State of Oregon
- Rulemaking - Department of Cannabis Control
- Federal Acquisition Regulation: List of Domestically Nonavailable Articles
- Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food and Drug Administration's Adverse Event and Product Experience Reporting Program
- Exempt Chemical Preparations Under the Controlled Substances Act